What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 2
- “The purpose of this study is to measure safety and the improvement in symptoms in subjects with ADHD when taking ALKS 7290 tablets compared with placebo tablets.”In the company’s words, NCT07755410 on ClinicalTrials.gov
Other drugs for Attention Deficit Disorder With Hyperactivity (ADHD)
- CentanafadineOtsuka · Phase 3
- AK-D101Alvogen Korea · Phase 3
- SolriamfetolAxsome Therapeutics, Inc. · Phase 3
- SPN-812Supernus Pharmaceuticals, Inc. · Marketed (Phase 4 trial)
Coming up2
- Jul 2027Phase 2 trial completes · ClinicalTrials.gov
- Jan 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Jul 2027 | A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201) | |
| Phase 2Recruiting | Jan 2028 | A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026